Xencor Reports 45.5% Confirmed Response Rate for XmAb819 at Selected Dose in Phase 1 Kidney Cancer Trial

• Xencor selected a proposed Phase 3 dose for XmAb819 following Phase 1 results presented at the ESMO Congress 2026.
• The treatment showed antitumor activity in heavily pretreated patients with advanced clear cell renal cell carcinoma; most confirmed responses remained ongoing.
• Adverse events were generally manageable, though severe events occurred; treatment discontinuations linked to adverse events were uncommon.
• A potential registration-enabling trial comparing XmAb819 with tivozanib is planned by the end of 2027.
• Plans include discussions with the FDA on a potential accelerated approval pathway for patients who have exhausted standard treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xencor Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261025921014) on October 25, 2026, and is solely responsible for the information contained therein.